RxDoctor Payments Data

Austin Bell, MD

Glaucoma Specialist · Rogers, ARNPI 1093008302

Payments from drug & device makers

$50,231in general payments, 2019–2025

Across 250 payments — averaging $200.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$16K
  • Glaukos Corporation$13K
  • Bausch & Lomb Americas Inc.$9K
  • Ivantis, Inc$8K
  • AbbVie$1K
  • Alcon$675
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$16,63065%
  • Speaking & faculty fees$260%
  • Travel & lodging$2,83911%
  • Food & beverage$5,65022%
  • Entertainment$620%
  • Other$2931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$568,371
Medicare patients
843
Services billed
3,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate489$17,401
LumiganBimatoprost42$16,525
SimbrinzaBrinzolamide/Brimonidine Tart56$11,131
MoxifloxacinMoxifloxacin Hcl451$9,687
Latanoprost793$7,277
VyzultaLatanoprostene Bunod18$7,150
RhopressaNetarsudil Mesylate18$6,880
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$6,696
RocklatanNetarsudil Mesylat/Latanoprost18$6,642
Fluorometholone86$6,510
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat441$6,436
Ketorolac Tromethamine357$5,936
CombiganBrimonidine Tartrate/Timolol24$5,707
Travoprost41$5,620
Brimonidine Tartrate301$2,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$1,439$22,23266 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$31$13,52236 claims
AlconSimbrinza$675$11,13156 claims
Bausch & Lomb Americas Inc.Vyzulta$8,873$7,15018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Rogers

Where these figures come from

Is this you, or does something look wrong? →